Cargando…
Critical appraisal of trastuzumab in treatment of advanced stomach cancer
Advanced or metastatic gastric cancer constitutes the majority of patients in clinical practice. In North America, about 70% of cases are advanced or metastatic when diagnosed, which is higher than the 50% reported in Japan. This difference in presentation is reflected in 5-year overall survival, wh...
Autores principales: | Meza-Junco, Judith, Au, Heather-Jane, Sawyer, Michael B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085240/ https://www.ncbi.nlm.nih.gov/pubmed/21556317 http://dx.doi.org/10.2147/CMR.S12698 |
Ejemplares similares
-
Metastatic gastric cancer – focus on targeted therapies
por: Meza-Junco, Judith, et al.
Publicado: (2012) -
Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Pal, Sumanta Kumar, et al.
Publicado: (2010) -
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013) -
Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
por: Aguiar-Bujanda, David, et al.
Publicado: (2015) -
Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
por: Tang, Shou‐Ching, et al.
Publicado: (2021)